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Mara Morello, MD,k and Laura Bergamasco, PhD{Purpose: Oral anticoagulant therapy (OAT) patients have international normalized ratio (INR) safety
windows for oral surgery, the lower limit of which is determined by the thromboembolic risk, with the
upper limit typically 3.0. We sought to assess whether these limits will also be true with comorbidities
that favor bleeding, such as diabetes, liver disease, and chronic renal failure.
Materials andMethods: The study was designed for 500 consecutive extractions. Patients with an INR
greater than 3.0were switched to heparin and used as controls. The primary outcomewas the incidence of
bleeding with the need for reoperation, in connection with 3 principal predictors: the INR, reasons for
OAT, and comorbidity type. Continuous variables were analyzed using the Mann-Whitney U test and cat-
egorical variables using c2 or Fisher’s exact test. Statistical significance was set at P < .05. The reliability of
the INR as a bleeding predictor was assessed using receiver operating characteristic (ROC) curves.
Results: Extractions in patients receiving OATwithout comorbidities had a success rate of 99.7% against
severe bleeding. Despite equivalent INR values, patients with comorbidities had a significantly lower rate
(81.3%, P < .001). For these patients, the ROC curve procedure indicated lower INR upper limits, 2.8 for
mechanical heart prosthesis subjects and 2.3 for all others. Among the comorbidities, diabetes was asso-
ciated with the greatest frequency of bleeding (31%) compared with liver disease (15%) and kidney failure
(11%).
Conclusions: Patients with comorbidities should be advised to bring their INR within narrower safety
windows (upper limit of 2.5 to 2.8 for mechanical prosthesis and 2.0 to 2.3 otherwise) or be switched
to heparin. Alternatively, we propose applying to the socket, a platelet-rich growth factor preparation
to foster hemostasis.
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COCERO ET AL 859The number of patients receiving oral anticoagulant
therapy (OAT) and requiring dental surgery has been
increasing simply owing to the increase in the elderly
population, who will also be the most afflicted by
various cardiovascular problems. Perioperative man-
agement in this population is both challenging and
clinically important, because it involves 2 main con-
cerns: the risk of thromboembolism, with anticoagula-
tion interruption, versus the risk of procedural or
postprocedural bleeding, with anticoagulation contin-
uation.1-3
In the past, many oral surgical procedures were per-
formed after the patient had interrupted OAT to be
switched to heparin. Switching to low-molecular-
weight heparin, however, does not allow tight control
of the patient’s coagulation state. In contrast, choosing
‘‘traditional’’ unfractionated heparin will increase the
hospitalization stay, because the infusion must be
managed in the hospital. Even then, it exposes a not-
insignificant number of patients to the side effects of
a continuous heparin infusion. Moreover, switching
increases the hemorrhagic risk, particularly in the
bridging phase, when both anticoagulants could be
acting simultaneously.
The prothrombin time (PT) is the laboratory test of
choice for monitoring the anticoagulation status of pa-
tients treated with oral anticoagulants. The standardi-
zation of PT with the international normalized ratio
(INR) allows for uniformmeasurements and permitted
the development of effective recommendations for the
use of oral anticoagulants in various clinical settings.
Patients with mechanical valves and those who have
experienced a thromboembolic event within 3 months
before the discontinuation of anticoagulation have been
considered to be at high risk of newor recurrent throm-
boembolism4-6 and have been advised to keep the INR
at 2.5 or greater. In contrast, patients receiving
anticoagulation for indications such as atrial fibrillation
will be at lower risk7,8 and can have an INR of 2.0 or
more. Factors that increase the risk level include age
older than 75 years, hypertension, stroke, transient
ischemic attack, and heart failure.9-11 In most cases, an
INR of at least 2.0 will be required for effective
anticoagulation. As the INR increases, the blood will
take longer to clot, and the patient will be at increased
risk of bleeding. Thus, there is an upper limit for the
allowable INR therapeutic levels in cases of surgery;
for dental extractions, it has generally been set at
an INR of 3.0 or less. However, this should be
considered a general limit, applied independently
of comorbidities. The present report presents the
results of a prospective study of 500 dental extractions
conducted in patients receiving OAT for prophylaxis
against cardioembolism.
Our hypothesis was that the validity of this INR limit
should not to be assumed correct in the case of patientsaffected by diabetes, liver disease, or kidney failure,12-14
pathologic entities that have been demonstrated to
hinder healing. We believed the issue needed to be
tested in a clinical trial designed specifically to address
the following questions:
1. Among all patients receiving OAT and undergoing
dental extraction with an INR of 3.0 or less, what
is the incidence of the most common postopera-
tive complications: severe bleeding needing reop-
eration and hematoma?
2. Does the presence of comorbidities often asso-
ciated with cardiovascular problems, such as
diabetes, liver disease, and kidney failure, exacer-
bate bleeding?
3. If the answer to question 2 is yes, could the prob-
lem be avoided by lowering the INR upper limit?
If so, what would be the advisable upper limit for
the INR for this particular subclass of patients?
Finally, could a new limit coexist with the lower
limits set according to thromboembolic risk?
The final goal was to determine the best scenario
capable of reconciling as much as possible the most
effective surgical conditions—minimum bleeding
and hematoma—with the most appropriate coverage
against thromboembolic risk in the various categories
of OAT patients.Materials and Methods
STUDY DESIGN AND SAMPLE
Our study was designed to include 500 consecutive
extractions in patients receiving OAT. The large num-
ber was chosen to allow division into the groups and
subgroups of interest without the loss of statisti-
cal power.
The study sample was derived from the population
of patients who were referred to the oral surgery sec-
tion of our institution (Dental School, University of
Torino, Azienda Ospedaliera Citta della Salute e della
Scienza of Torino; 1 of the largest hospitals in northern
Italy) by in-hospital departments, general practi-
tioners, or cardiologists. Because of the high turnover
at the hospital, the target of 500 extractions was
reached within slightly less than 1 year.
To be included, the patients had to be receiving OAT,
need a dental extraction because of root or crown frac-
tures, nonrestorable caries, residual roots, or peri-
odontal and endodontic abnormalities, and be willing
to cooperatewith the study protocol and follow-up pro-
gram. No exclusion criteriawere applied regarding age,
gender, or associated comorbidity; however, the pa-
tients were required, according to the present protocol
at our hospital, to have an INR value of 3 or less. Patients
with an INR greater than 3.0 were switched to heparin
and were used as controls for the OAT patients.
860 BLEEDING DURING ORAL SURGERY OF OAT PATIENTSAll patients provided written informed consent
before enrolling. The study was conducted in accor-
dance with the Declaration of Helsinki, as updated,
and was approved by the local ethics committee.
SURGICAL PROTOCOL
The same surgeon, with extensive clinical experi-
ence, performed all extractions. After the induction
of local anesthesia (mepivacaine 3% without adrena-
line), the teeth were extracted in a nontraumatic
manner, with rotation and traction movement using
dental forceps and elevators. The alveolar sockets
were first treated with a fibrin sponge (Spongostan,
Ethicon, Cincinnati, OH) and then sutured with 3-0
silk thread; the sutures were removed after 7 days.
Analgesic therapy (paracetamol 1,000, 1 tablet twice
daily for 2 days) was provided. Antibiotic prophylaxis
was given when necessary. The same postoperative in-
structions were given to all the patients. The surgeon
who performed the extractions checked each patient
at 1, 3, and 7 days after the extraction to assess the
healing process and the possible presence of severe
bleeding and/or hematoma. Additional follow-up ses-
sions were added as needed.
STUDY VARIABLES
At baseline, the patients were characterized accord-
ing to the following variables: age, gender, tooth to be
extracted (molar, premolar, canine, or incisor and rela-
tive arcade), number of extractions, number of ses-
sions, reasons for OAT, drug used for OAT, INR value,
and the presence of diabetes, liver disease, and chronic
renal failure. The principal predictor variables were
the INR, reason for OAT, and type of comorbidity.
The adverse events rate was evaluated as a function
of each baseline variable, with particular emphasis on
the 3 principal predictors.
Theprimaryoutcomevariable of interestwas the inci-
dence of severe bleeding at the 3 follow-up sessions; the
secondary variable was the incidence of hematoma.
Severe bleeding was defined as bleeding not manage-
able by the patient, extending into the days after the
extraction and requiring reintervention by a surgeon
to remove the build-up of the necrotic clot. This will
create damage, although minimal, and discomfort for
the patient, because of the necessity to intervene in a
wound still in the process of healing, with possibly
edematous tissues. Such hematomas do not represent
a danger to thepatient, only a temporaryestheticdeficit,
typically of short duration. However, these will never-
thelessoftenbeconsidereddisturbingbymanypatients.
STATISTICAL ANALYSIS
The statistical analysis involved continuous, binary,
and categorical variables. The former, reported as themean standard deviation, were compared using anal-
ysis of variance and the nonparametric Mann-Whitney
U test. Binary and categorical variables are reported
as counts and percentages, with 95% confidence inter-
vals (CIs), arranged in 2 2 or r c contingency tables
and examined using the c2 test (with Yates’ correction
for 2 2) or, where appropriate, Fisher’s exact test. The
risk ratio (RR) was computed with its 95% CI. Statistical
significance was set at P < .05.
The discriminatory ability of the INR as an indicator
of possible bleeding problems was assessed using a
receiving operating characteristic (ROC) curve,
commonly used in medical studies to determine the
cutoff values for clinical tests. The ROC curve is a
graph of the true-positive rate (ie, sensitivity) versus
the false-positive rate (ie, 1 specificity). The area un-
der the resulting curve (AUC) measures the accuracy
of discrimination, ranging from 0.5 (no discrimination)
to 1 (perfect). The cutoff value will be chosen to mini-
mize the number of false-positive and false-negative re-
sults (ie, maximize the sensitivity and specificity;
because they have opposite behaviors, their simulta-
neous maximization is performed by maximizing their
harmonic mean). To increase the reliability of the
determination, we also used the simultaneous maximi-
zation of Cohen’s coefficient, k, associated with the
ROC curve.Results
The 500 extractions were performed in 166 patients
with an average age of 72.1  10.4 years (range 23
to 89); 42.7% were women. Each patient underwent
1.5  0.9 surgery sessions (range 1 to 6) and 2.5  2.3
extractions (range 1 to 13).
The outcome of each extraction was characterized
by the binary conditions of bleeding (yes vs no) and he-
matoma (yes vs no). Figure 1 illustrates the sequence
of stages in the extraction of 4 teeth with no postoper-
ative complications in a patient with a mechanical
heart valve. Figure 2 shows 2 typical cases of adverse
events: severe bleeding with the need for reinterven-
tion and a long-lasting hematoma. No complication
was observed after the day 7 follow-up examination.
The patients were subdivided into 4 groups accord-
ing to their reason for requiring OAT. Their principal
characteristics are listed in Table 1.
Group A (patients who had been switched to hepa-
rin) included 24% with an artificial cardiac valve. In
this group, 25 had a comorbidity: 44% had diabetes,
28% had liver disease, and 28% had kidney failure.
Their INR ranged from 0.92 to 1.5 (average 1.18 
0.19). As expected, no severe bleeding was observed
in this group, neither in the subgroup with comorbid-
ities nor in those without, and only 1 hematoma was
observed in the second subgroup. Group A was used
FIGURE 1. Typical evolution of a case with no adverse events. Extraction of 4 teeth was performed simultaneously in a patient with a mechan-
ical heart valve.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral Maxillofac Surg 2014.
COCERO ET AL 861as the control group for the 3 groups of patients
receiving OAT.
Groups B, C, and D included 435 extractions per-
formed on patients receiving standard OAT (91.6%FIGURE 2. Two typical cases with adverse events. One patient experie
developed a long-lasting hematoma.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral Maxireceiving warfarin and 8.4% acenocoumarin). Of these
patients, 107 (24.6%) had comorbidities. The results of
our trial showed very good outcomes for the 328
dental extractions performed in patients withoutnced severe bleeding with the need for reintervention and another
llofac Surg 2014.
Table 1. PATIENT CHARACTERISTICS
Group
Extractions
(n)
INR
Safety
Window
Comorbidity
Present (%)
A (switched to
heparin)
65 NA 35
B (biologic
cardiac valves)
38 2.0-3.0 18
C (mechanical
cardiac valves)
133 2.5-3.0 18
D (all other
cardiovascular
diseases)
264 2.0-3.0 29
Abbreviations: INR, international normalized ratio; NA, not
applicable.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.
Table 2. RESULTS FOR GROUP C (MECHANICAL
CARDIAC VALVES)
Variable
No
Comorbidity Comorbidity P Value
Patients (n) 109 24
Age (yr) 69.0  11.7 58.7  10.1 .0001*
INR 2.77  0.28 2.84  0.12 .23
Severe bleeding 3/109 (2.8) 8/24 (33.3) 105*
Hematoma 3/109 (2.8) 6/24 (25.0) 5  104*
Data presented as mean  standard deviation or n (%).
Abbreviation: INR, international normalized ratio.
* Statistically significant.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.
862 BLEEDING DURING ORAL SURGERY OF OAT PATIENTScomorbidities, with a success rate of 99.7% (95% CI
98.5% to 100%) against bleeding and 98.8% (95% CI
97.1% to 99.6%) against hematoma formation.
The outcomes for the 107 extractions performed in
those with comorbidities was less satisfactory. The
success rate was 81.3% (95% CI 73.1% to 87.9%)
against bleeding and 90.7% (95% CI 84.0% to 95.2%)
against hematoma formation. The differences between
the adverse event rates in the comorbidity and no-
comorbidity samples were statistically significant
(P < 107), with a RR of 61 (95% CI 8 to 451) for
bleeding and RR of 8 (95% CI 3 to 24) for hematoma
formation (P = .0001). Thus, patients with comorbid-
ities had a markedly greater chance of experiencing
these adverse events.
The incidence of severe bleeding and hematoma
were not influenced by gender (P = .85) or by the
type of drug used for OAT (P = .45). An apparent differ-
ence was seen with age, with younger people seem-
ingly the most affected (P = .0003), but this was
likely because the comorbidities increased the rate of
adverse events significantly, and the patients with
comorbidities were significantly younger than the
patients without (68.5  11.8 vs 73.9  9.5 years;
P = 2  105).
Severe bleeding with regard to tooth type was, as
expected, greater for molars (17.2%) than for pre-
molars (1.4%) and incisors and canines (1.0%; P =
2  106, RR 15, 95% CI 4 to 64), regardless of
the arcade (P = .78). The prevalence of molar cases
was similar between those with and without co-
morbidities.
In the following subsections, we present the results
of the 3 groups (B, C, and D) separately and their com-
parison with the control (group A).GROUP B: BIOLOGIC CARDIAC VALVES
In group B, the extractions were in patients
receiving OAT because of recently implanted biolog-
ical cardiac valves (7 with comorbidities). The INR in
the presence and absence of comorbidities was essen-
tially identical: 2.29  0.30 (range 1.90 to 2.98) and
2.17  0.26 (range 1.80 to 2.40; P = .29). Group B
was free from adverse events, with no severe bleeding
and no hematoma, consistent with the results of the
control group (group A).GROUP C: MECHANICAL CARDIAC VALVES
In group C, the extractions were performed in pa-
tients receiving OAT because they had mechanical car-
diac valves. These patients, considered at high risk of
new or recurrent thromboembolism, had an INR of
2.5 or more but not greater than 3.0. This value had
been met by those with comorbidities; however, 13%
of those without comorbidities had an INR of 1.81 or
more but less than 2.5.
The presence of comorbidities had a considerable
negative effect (Table 2). Despite a statistically signifi-
cantly younger age and similar INR, the bleeding and
hematoma rates were significantly greater for those
with comorbidities than for those without. The differ-
ences were striking: for the bleeding rate, P = 105,
with a very high RR of 12 (95% CI 4 to 42) and for
the hematoma rate, P = 5  104 and RR of 9 (95%
CI 2 to 34) for comorbidities.
The outcomes in the no-comorbidity subgroup in
group C was essentially similar to its counterpart in
the control group (P = .69 for bleeding and P = .63
for hematoma). The situation was markedly different
when comparing the comorbidity subgroups within
the 2 groups (P = .006 for bleeding and P = .03 for he-
matoma, against group C).
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Group D included extractions in patients receiving
OAT because of cardiovascular problems other than
those related to heart valves, mainly atrial fibrillation
and venous thromboembolism. Their thromboem-
bolic risks are lower than those associated with me-
chanical prostheses; thus, their INR lower limit has
been placed by cardiologists at 2.0. This limit, how-
ever, was not observed in 36% of our patients in the
no-comorbidity subgroup and 14% in the comorbidity
subgroup.
The outcomes for group D are listed in Table 3. The
pattern that emerged was similar to that seen for
Group C. Despite a younger age and equivalent INR,
the comorbidity subgroup had bleeding and hema-
toma rates both significantly greater than those for
the no-comorbidity subgroup (P = 106 and P = .03,
respectively). Also, the no-comorbidity subgroup of
group D had results very similar to those of the control
group (group A). In contrast, the comparison between
the comorbidity subgroups of the 2 groups yielded P =
.0008 for the bleeding rate and P = .31 for the hema-
toma rate against group D (for hematomas, the test po-
wer was very low,P = 20%, corresponding to a b error
of 0.80; to reach the conventionally accepted value of
P = 80%, the sample sizes would have needed to be at
least 4 times larger).
DETERMINATION OF INR UPPER SAFETY LIMITS FOR
OAT PATIENTS WITH COMORBIDITIES
The present results have shown that patients in
groups C and D with no associated comorbidities pre-
sented with the same low bleeding and hematoma
rates as patients in the control group (group A). In
contrast, patients with associated comorbidities had
markedly greater numbers of adverse events.
The INR values for the comorbidity subgroups of
groups C and D, subdivided into bleeding and non-
bleeding extractions, are listed in Table 4. For bothTable 3. RESULTS OF 133 EXTRACTIONS IN GROUP
D (OTHER CARDIOVASCULAR DISEASES)
Variable
No
Comorbidity Comorbidities P Value
Patients (n) 188 76
Age (yr) 76.1  7.5 70.2  11.2 .00005*
INR 2.34  0.35 2.30  0.26 .37
Severe bleeding 0/188 (0.0) 12/76 (15.8) 106*
Hematoma 1/188 (0.5) 4/76 (5.3) .03*
Data presented as mean  standard deviation or n (%).
Abbreviation: INR, international normalized ratio.
* Statistically significant.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.groups, the INR relative to extractions followed by
bleeding was significantly greater than those whose
extractions were not followed by bleeding, confirming
our hypothesis that the INR limit of 3 or less, pre-
scribed in standard surgical protocols as a safeguard
against bleeding, might actually be inappropriate in
the presence of comorbidities.
To determine the safe upper limits for the INR, we
followed standard ROC curve procedures. Figure 3
shows that the 2 INR distributions relative to bleeding
and nonbleeding in groups C and D tended to occupy
distinct regions of the INR axis, with the bleeding
component shifted toward greater values and a limited
region of overlap. These distributions were used as the
inputs for the 2 ROC curves plotted in Figure 4A.
For group C (mechanical valves), the AUC of the
ROC curve was 0.86 (95% CI 0.71 to 1.00), a value
generally considered ‘‘very good.’’ Maximization of
the harmonic mean of the specificity and sensitivity
and of Cohen’s index, k, put the threshold between
not bleeding and bleeding at an INR of 2.8 (Fig 4B).
The total number of extractions under this limit was
9, with zero bleeding (0%). In contrast, for an INR of
greater than 2.8 but 3 or less, bleeding occurred in 8
of 15 patients (53.3%), with a statistically significant
difference (P = .02), confirming the discriminant abil-
ity of the derived cutoff.
For group D (other cardiovascular disease), the AUC
was 0.73 (95% CI 0.60 to 0.86), a value generally
considered ‘‘good,’’ with a threshold set at an INR of
2.30 (Fig 4C). At less than this limit, bleeding occurred
in 1 of 31 (3.2%). In contrast, for an INR of less than 2.3
but 3 or less, it increased to 11 of 46 (23.9%). Compar-
ison of the former and latter yielded P = .03 and RR of 7
(95% CI 1 to 54).
The results of the ROC curve procedure indicated
that, in the presence of comorbidities, the INR upper
limit should be lowered from the general value of 3.0
to the 2 more specific limits of 2.8 for group C and
2.3 for group D. The improvement in bleeding rates
thus obtained (0% vs 33% for group C and 3% vs 16%
for group D) is clearly visible in Figure 5.
How setting these new upper limits affected only
the comorbidity subgroups is presented in Table 5.
At less than these new thresholds, the presence or
absence of comorbidities will be irrelevant, with low
bleeding rates regardless. In contrast, at greater than
these thresholds, the presence of comorbidities was
the factor that increased the bleeding rate significantly.BLEEDING RATE ACCORDING TO COMORBIDITY
The comorbidities considered were diabetes, liver
disease, and kidney failure. Figure 6 shows their asso-
ciation with bleeding: diabetes led with 12 bleeding
cases in 39 patients (30.8%), a rate twice as great as
Table 4. PARAMETERS OF TWO COMORBIDITY SAMPLES IN GROUP C (MECHANICAL VALVES) ANDGROUP D (OTHER
CARDIOVASCULAR DISEASES)
Variable
Group C (No Comorbidities, n = 24) Group D (No Comorbidities, n = 76)
Bleeding No Bleeding P Value Bleeding Non-Bleeding P Value
Extractions 8 (33.3) 16 (66.7) NA 12 (15.8) 64 (84.2) NA
INR 2.93  0.04 2.79  0.11 .002 2.44  0.17 2.27  0.26 .036
Data presented as mean  standard deviation or n (%).
Abbreviations: INR, international normalized ratio; NA, not applicable.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral Maxillofac Surg 2014.
864 BLEEDING DURING ORAL SURGERY OF OAT PATIENTSthat for those with liver disease (5 of 33; 15.6%) or kid-
ney failure (3 of 28; 10.7%). The difference was, how-
ever, of only borderline statistical significance (P =
.09), possibly because of the small numbers involved.
A more powerful comparison could be performed by
considering the bleeding rate for those with diabetes
versus the bleeding rate for the other 2 comorbidities
combined (ie, 8 of 61; 13.3%). The c2 test, applied to
the resulting 2  2 table yielded P = .058; however,
the RR was 2.4 (95% CI 1.1 to 5.2) pointing to diabetes
as the most important among the 3 associated patho-
logic entities.FIGURE 3. A, International normalized ratio (INR) distributions for
mechanical valve patients (group C). B, INR distributions for patients
with other cardiovascular diseases (group D). B, bleeding; NB, no
bleeding.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.
FIGURE4. A, Receiver operating characteristic (ROC) curves, with
area under the curve of 0.86 for mechanical valves and 0.73 for
other cardiovascular disease. B, Harmonic mean (HM) of sensitivity
and specificity and Cohen’s index, k, plotted as a function of the
INR. The value at which they reach their maximum identifies the
best cutoff (INR 2.8 for mechanical valves and 2.3 for other cardio-
vascular diseases).
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.
FIGURE 6. Number of bleeding (B) and no-bleeding (NB) extrac-
tions in patients with comorbidities (groups C and D).
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.
FIGURE5. Bleeding rates using the surgical upper limit of the inter-
national normalized ratio (INR) of 3.0 compared with those
obtained using the lower values indicated by the receiver operating
characteristic (ROC) curves (INR 2.8 for group C [mechanical
valves] and 2.3 for group D [others]).
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.
COCERO ET AL 865The type of comorbidity had no effect on the INR
value. In group C, the INR was 2.85  0.09 for those
diabetes versus 2.83  0.14 (P = .44) for those with
liver or kidney disease. For Group D, the INR was
2.27  0.26 for those with diabetes versus 2.32 
0.26 for those with liver or kidney disease (P = .41).
Discussion
The present analysis of 500 dental extractions in pa-
tients receiving OAT showed that their outcomes, in
terms of bleeding and hematoma, were the result of
the cumulative and intertwined effects of the INR,
the reasons underlying the OAT, and the presence
and types of comorbidities. The most used INR upper
limit for surgical procedures (INR # 3.0) did notTable 5. BLEEDING RATES IN GROUPS C AND D AT
GREATER THAN AND LESS THAN THE ROC CUTOFF
Group
No
Comorbidity Comorbidities P Value
C (mechanical
valves)
INR > 2.8 2/50 (4) 8/15 (53) 9  105
INR # 2.8 1/59 (2) 0/9 (0) $.99
P value .88 .02 —
Group D
(others)
INR > 2.8 0/95 (0) 11/46 (24) 4  106
INR # 2.8 0/93 (0) 1/30 (3) .49
P value >.99 .03
Data presented as n (%).
Abbreviations: INR, international normalized ratio; ROC,
receiver operating characteristic.
Cocero et al. Bleeding During Oral Surgery of OAT Patients. J Oral
Maxillofac Surg 2014.consider the issue of comorbidities associated with
cardiovascular problems. We investigated whether
the INR limit of 3.0 or less would be valid in patients
with comorbidities, such as diabetes, liver disease,
and kidney failure. We hypothesized that because
these pathologic entities are known to hinder healing,
patients with any of them might be exposed to a non-
negligible number of adverse events and should thus
be safeguarded differently from patients without
such comorbidities. The outcomes of 65 extractions
in patients who had been switched to heparin (group
A) were used as controls for the results of the dental
extractions in patients receiving OAT.
Overall, the results confirmed our hypothesis. The
success rate against bleeding was 99.7% for the 328
dental extractions performed in patients receiving
OAT who did not have comorbidities. However, it
was only 81.3% for the 107 extractions performed in
patients with comorbidities.
The 435 extractions were subdivided into 3 groups
for a more detailed analysis according to the reason for
OAT: group B, biological cardiac valves; group C, me-
chanical cardiac valves; and group D, all other cardio-
vascular diseases. Our results showed that patients
receiving OAT after the insertion of biologic cardiac
valves (group B) can be considered at low risk, not
only of thromboembolism, but also of severe bleeding.
For these patients, the previous upper limit of an INR
of 3.0 worked well.
The issue of comorbidities was crucial in groups
C and D, increasing the rate of adverse events markedly,
especially severe bleeding with the need for reopera-
tion. In group C, those with comorbidities experienced
a 33% bleeding rate, significantly greater than the
2.8% rate in the no-comorbidity subgroup (P < .001).
Similarly, in group D, the comorbidity subgroup
had a much greater bleeding rate than did the no-
comorbidity subgroup (15.8% vs 0%; P = 106).
866 BLEEDING DURING ORAL SURGERY OF OAT PATIENTSContinuing from the hypothesis that the INR limit of
3 or less for most oral surgery protocols might actually
need to be lowered for patients in groups C and Dwith
comorbidities, we used the standard ROC curve proce-
dure to determine more appropriate cutoff values. For
group C, the ROC curve analysis indicated the upper
limit of the safety window should be set at an INR of
2.8 instead of at 3.0. In our sample, this would have
reduced the bleeding rate from 33% to 0%. For group
D, the new limit was an INR of 2.3, leading to a reduc-
tion in the bleeding rate from 16% to 3%. For patients
without comorbidities, we found no need to reduce
the standard upper INR limit.
Among the comorbidities, diabetes was the most
important, with the greatest degree of an association
with bleeding (31%) compared with liver disease
(15%) and kidney failure (11%). This propensity of dia-
betes to induce bleeding might have resulted from the
alteration in glucose metabolism, which can cause
dysfunction in polymorphonuclear leukocytes and fi-
broblasts, increasing the susceptibility to infection
and impaired healing. This has been seen after dental
extractions, with a slowing of the formation and
replacement of the blood clot, inducing recurrent
bleeding in the days after the extraction, and increasing
the risk of bacterial infection. In patients with chronic
liver disease, local infections and impairedwoundheal-
ing have been favored by the conditions of immuno-
suppression and the reduced capacity for protein
synthesis by hepatocytes. Hemostasis problems can
be induced, not only by the reduced production of
vitamin K-dependent factors, but also by hyperfibrinol-
ysis and thrombocytopenia, owing to secondary hyper-
splenism caused by portal hypertension. Finally,
kidney failure can cause impaired healing because of
uremic conditions, which inhibit the proliferation of fi-
broblasts and endothelial cells within the granulation
tissue. Toxin build-up in the blood can also cause he-
mostatic disorders owing to platelet dysfunction.
The results of our study can be interpreted as fol-
lows. The physiologic process of normal hemostasis,
epithelialization, and maturation of the wound left af-
ter dental extraction occurs by the interaction among
many biologic systems, involving blood vessels, plate-
lets, and coagulation factors. OAT upsets the equilib-
rium of this system through drug-induced inhibition
of the coagulation cascade, with the intention of
reducing the thromboembolic risk. In patients
without comorbidities, coagulation will generally be
sufficient to prevent serious hemorrhage as long as
the INR remains less than 3.0. The presence of comor-
bidities, such as diabetes, liver disease, and kidney fail-
ure, however, tilts the balance toward bleeding by
acting at different levels of the chain of processes
that control coagulation, shifting the maximum allow-
able INR lower. The contest between coagulation andbleeding-inducing factors is reflected in the INR distri-
bution shown in Figure 3. For a low INR, for which
coagulation prevails, nonbleeding extractions were
dominant. In contrast, for a high INR, for which coag-
ulation succumbs, bleeding extractions were domi-
nant. In the intermediate region, at which the
coagulation and bleeding factors were even, bleeding
and nonbleeding extractions shared the territory.
The cutoff limits derived for the comorbidity sub-
groups in groups C and D reflect the borderline across
which coagulation is replaced by bleeding. Thus, for
group C, for which coagulation will be a highly active
(and, from a cardiovascular viewpoint, very risky) pro-
cess, the INR limit was higher (INR = 2.8) than for
group D (INR = 2.3).
In conclusion, the results of our trial showed very
good outcomes (success rate close to 100%) for dental
extractions performed using the standard surgical
limit of an INR of 3 or less for patients without comor-
bidities. For patients with comorbidities, the ROC
curve procedure suggested lowering the maximum
allowable INR, from 3.0 to 2.80 for those withmechan-
ical valves (minimum value 2.5) and 2.30 for other car-
diovascular patients (minimum value 2.0) to reduce
the risk of bleeding. This suggestion, even if sound sta-
tistically, is, however, not without drawbacks from a
clinical viewpoint. It is not easy to simply alter doses
to bring the patient’s original INR within these narrow
safety windows, which was seen for several patients
who arrived with an INR lower than that prescribed
in an attempt to reduce the bleeding risk, but leaving
them exposed to a greater risk of thromboembolic
complications. Furthermore, the process of reducing
the INR requires several days, necessarily delaying
the dental extraction. However, the patients often
require an urgent intervention because of extreme
pain or proximity to a major surgery.
To satisfy the need to balance the thromboembolic
and bleeding risks, 1 solution could be to switch all pa-
tients with comorbidities, in particular those with dia-
betes, to heparin. However, this also is no panacea.
Low-molecular-weight heparin does not allow the
necessary control of patients’ coagulation state, and
‘‘traditional’’ unfractionated heparin increases the
duration of hospitalization. Furthermore, the very pro-
cess of switching can also increase the hemorrhagic
risk in the intermediate phase when the anticoagulant
action of OAT has not yet completely declined and
heparin has started to work.
On the basis of previous experience with several
pathologic entities in our oral surgery unit, we have
seen a totally different approach as an intriguing alter-
native, in which the oral surgeon addresses the
bleeding issue ‘‘on-site’’ and in real time during the
extraction using a platelet-rich growth factor (PRGF)
preparation on the wound resulting from the dental
COCERO ET AL 867extraction. These platelet gels are concentrated prep-
arations of autogenous platelets, which play a role in
hemostasis, preventing bleeding at sites of vascular
injury. They do so by forming a procoagulant surface,
with thrombin generation and fibrin formation. Plate-
lets also release substances favoring tissue repair and
influencing the reactivity of vascular and other blood
cells in angiogenesis and inflammation.15 The use of
blood-derived products to seal wounds and stimulate
healing was originally proposed by Kingsley.16 The
first application of autologous fibrin glue in oral sur-
gery was reported in 1994 by Tayapongsak et al,17
who used autologous fibrin adhesive as a medium for
compacting grafts, and its use has increased ever since.
Our center has used PRGF in patients with systemic
pathologic entities. Positive results, in terms of
enhancement of hemostatic action and epithelial
closure, have been obtained with thrombocytopenic
patients,18 patients receiving bisphosphonate ther-
apy,19,20 patients with insulin-dependent diabetes mel-
litus,21 and patients who had undergone radiotherapy
for head and neck cancer.22 Other studies have been
conducted of hemophiliac patients and liver trans-
plant candidates. We are thus confident in suggesting
that a similar procedure could also be successful in pa-
tients receiving OAT, who could thus keep the stan-
dard upper limit at an INR of 3 without an increased
bleeding risk. Also, in patients without comorbidities,
the use of PRGF might allow increasing the INR upper
limit to values greater than 3.0, without affecting OAT.
A study is being initiated to assess this.
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